Impact of systemic inflammation and autoimmune diseases on apoA-i and HDL plasma levels and functions
© The Author(s) 2015. The cholesterol of high-density lipoproteins (HDLs) and its major proteic component, apoA-I, have been widely investigated as potential predictors of acute cardiovascular (CV) events. In particular, HDL cholesterol levels were shown to be inversely and independently associated...
| Main Authors: | , , , , , |
|---|---|
| Format: | Conference Paper |
| Published: |
2015
|
| Online Access: | http://hdl.handle.net/20.500.11937/55637 |
| _version_ | 1848759671055187968 |
|---|---|
| author | Montecucco, F. Favari, E. Norata, Giuseppe Ronda, N. Nofer, J. Vuilleumier, N. |
| author_facet | Montecucco, F. Favari, E. Norata, Giuseppe Ronda, N. Nofer, J. Vuilleumier, N. |
| author_sort | Montecucco, F. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | © The Author(s) 2015. The cholesterol of high-density lipoproteins (HDLs) and its major proteic component, apoA-I, have been widely investigated as potential predictors of acute cardiovascular (CV) events. In particular, HDL cholesterol levels were shown to be inversely and independently associated with the risk of acute CV diseases in different patient populations, including autoimmune and chronic inflammatory disorders. Some relevant and direct anti-inflammatory activities of HDL have been also recently identified targeting both immune and vascular cell subsets. These studies recently highlighted the improvement of HDL function (instead of circulating levels) as a promising treatment strategy to reduce inflammation and associated CV risk in several diseases, such as systemic lupus erythematosus and rheumatoid arthritis. In these diseases, anti-inflammatory treatments targeting HDL function might improve both disease activity and CV risk. In this narrative review, we will focus on the pathophysiological relevance of HDL and apoA-I levels/functions in different acute and chronic inflammatory pathophysiological conditions. |
| first_indexed | 2025-11-14T10:03:35Z |
| format | Conference Paper |
| id | curtin-20.500.11937-55637 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:03:35Z |
| publishDate | 2015 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-556372017-09-13T16:11:11Z Impact of systemic inflammation and autoimmune diseases on apoA-i and HDL plasma levels and functions Montecucco, F. Favari, E. Norata, Giuseppe Ronda, N. Nofer, J. Vuilleumier, N. © The Author(s) 2015. The cholesterol of high-density lipoproteins (HDLs) and its major proteic component, apoA-I, have been widely investigated as potential predictors of acute cardiovascular (CV) events. In particular, HDL cholesterol levels were shown to be inversely and independently associated with the risk of acute CV diseases in different patient populations, including autoimmune and chronic inflammatory disorders. Some relevant and direct anti-inflammatory activities of HDL have been also recently identified targeting both immune and vascular cell subsets. These studies recently highlighted the improvement of HDL function (instead of circulating levels) as a promising treatment strategy to reduce inflammation and associated CV risk in several diseases, such as systemic lupus erythematosus and rheumatoid arthritis. In these diseases, anti-inflammatory treatments targeting HDL function might improve both disease activity and CV risk. In this narrative review, we will focus on the pathophysiological relevance of HDL and apoA-I levels/functions in different acute and chronic inflammatory pathophysiological conditions. 2015 Conference Paper http://hdl.handle.net/20.500.11937/55637 10.1007/978-3-319-09665-0_14 restricted |
| spellingShingle | Montecucco, F. Favari, E. Norata, Giuseppe Ronda, N. Nofer, J. Vuilleumier, N. Impact of systemic inflammation and autoimmune diseases on apoA-i and HDL plasma levels and functions |
| title | Impact of systemic inflammation and autoimmune diseases on apoA-i and HDL plasma levels and functions |
| title_full | Impact of systemic inflammation and autoimmune diseases on apoA-i and HDL plasma levels and functions |
| title_fullStr | Impact of systemic inflammation and autoimmune diseases on apoA-i and HDL plasma levels and functions |
| title_full_unstemmed | Impact of systemic inflammation and autoimmune diseases on apoA-i and HDL plasma levels and functions |
| title_short | Impact of systemic inflammation and autoimmune diseases on apoA-i and HDL plasma levels and functions |
| title_sort | impact of systemic inflammation and autoimmune diseases on apoa-i and hdl plasma levels and functions |
| url | http://hdl.handle.net/20.500.11937/55637 |